Mitchell Kapoor, an analyst from H.C. Wainwright, maintained the Buy rating on Century Therapeutics (IPSC – Research Report). The associated price target was lowered to $11.00.
Mitchell Kapoor has given his Buy rating due to a combination of factors, primarily hinging on Century Therapeutics’ promising clinical trial data and strategic expansion into the treatment of autoimmune diseases. Century’s ongoing clinical trial, ELiPSE-1, for its cell therapy product CNTY-101 in B-cell malignancies, has shown encouraging results, with responses observed in patients. The upcoming data release at the ASCO Annual Meeting is highly anticipated, as it will provide further insights into the efficacy and safety of higher dose levels and the potential sustained response in patients. This, coupled with the development of their proprietary Allo-Evasion technology, aims to improve on the durability of treatment responses, a key factor in the long-term success of cell therapies.
Moreover, Mitchell Kapoor’s optimism is bolstered by Century’s expansion into autoimmune diseases, with lupus being a particular focus. The initiation of a Phase 1 trial in systemic lupus erythematosus (SLE) and the expected data by the end of the year represent a significant milestone that could position Century at the forefront of innovative treatments in this space. Financially, Century has outperformed expectations with a lower net loss per share than forecasted and has secured a cash position that suggests a robust operational runway into 2026. Despite a slight decrease in the price target, the overall financial health of the company and the strategic milestones ahead contribute to Kapoor’s Buy rating.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Century Therapeutics (IPSC) Company Description:
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
Read More on IPSC:
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics price target lowered to $9 from $10 at Piper Sandler
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
